BusinessTeneoBio’s Next Gen Multivalent anti-BCMAxCD3, TNB-383B, and Anti-BCMA UniDabs for CAR T-Cell Therapy of Multiple Myeloma Highlighted at the American Society of HematologyBy Nasdaq OMXDec 11, 2017, 1:00 PM UTC
BusinessTeneobio’s Next Generation T Cell Redirection Antibody Platform for Cancer Biotherapeutics Offers Prospects of Reducing Cytokine ReleaseBy Nasdaq OMXMay 1, 2017, 12:01 PM UTC
